These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3798406)

  • 1. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway.
    Brace LD; Issleib S; Fareed J
    Thromb Res; 1986 Nov; 44(3):417-8. PubMed ID: 3798406
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway.
    Mikhailidis DP; Barradas MA; Dandona P
    Thromb Res; 1986 Jun; 42(5):719-20. PubMed ID: 3715827
    [No Abstract]   [Full Text] [Related]  

  • 3. Potentiation of endoperoxide analog-induced platelet aggregation by heparin.
    Mehta P; Mehta J
    Thromb Res; 1982 Jan 1-15; 25(1-2):91-9. PubMed ID: 7064132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepoxilin analog PBT-3 inhibits heparin-activated platelet aggregation evoked by ADP.
    Reynaud D; Hinek A; Pace-Asciak CR
    FEBS Lett; 2002 Mar; 515(1-3):58-60. PubMed ID: 11943194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway.
    Brace LD; Issleib S; Fareed J
    Thromb Res; 1985 Aug; 39(4):533-9. PubMed ID: 4049330
    [No Abstract]   [Full Text] [Related]  

  • 6. Heparin-induced platelet aggregation and its inhibition by antagonists of the thromboxane pathway.
    Cofrancesco E; Colombi M; Fowst C; Pogliani EM
    Thromb Res; 1986 Jun; 42(6):867-8. PubMed ID: 3726806
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P; Ferrario CM; Brosnihan KB
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation.
    Greer IA; Walker JJ; McLaren M; Calder AA; Forbes CD
    Thromb Haemost; 1985 Aug; 54(2):480-4. PubMed ID: 2867620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of heparin on platelet aggregation and release and thromboxane A2 production.
    Mohammad SF; Anderson WH; Smith JB; Chuang HY; Mason RG
    Am J Pathol; 1981 Aug; 104(2):132-41. PubMed ID: 7258300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New drugs for the inhibition of the pro-thrombotic effects of prostaglandins and thromboxane A2].
    Patscheke H
    Verh Dtsch Ges Inn Med; 1990; 96():696-702. PubMed ID: 2092508
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation.
    Mehta P; Lawson D; Ward MB; Lee-Ambrose L; Kimura A
    Cancer Res; 1986 Oct; 46(10):5061-3. PubMed ID: 3463411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition.
    Fang W; Wei J; Han D; Chen X; He G; Wu Q; Chu S; Li Y
    Thromb Res; 2014 Apr; 133(4):610-5. PubMed ID: 24525312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
    Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
    J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
    Johnson GJ; Leis LA; Francis GS
    Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.
    Kopia GA; Kopaciewicz LJ; Ohlstein EH; Horohonich S; Storer BL; Shebuski RJ
    J Pharmacol Exp Ther; 1989 Sep; 250(3):887-95. PubMed ID: 2528630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-induced platelet activation: the role of thromboxane A2 synthesis and the extent of platelet granule release in two patients.
    Kappa JR; Fisher CA; Addonizio VP
    J Vasc Surg; 1989 Apr; 9(4):574-9. PubMed ID: 2709525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments of TXA2 antagonists.
    Hamanaka N
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():663-5. PubMed ID: 2526556
    [No Abstract]   [Full Text] [Related]  

  • 20. Rational design of thromboxane A2 antagonists.
    Hamanaka N; Seko T; Miyazaki T; Kawasaki A
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():359-62. PubMed ID: 1825570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.